CoChat
Sign Up
Cited by 277Treatment of Major DepressionChronic Obstructive Pulmonary Disease (COPD) ResearchAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease

Borson, Soo, McDonald, Gwendolyn J., Gayle, Terence, Deffebach, Mark, Lakshminarayan, S., VanTuinen, Craig·1992·Psychosomatics
DOI 10.1016/s0033-3182(92)71995-1
Open this paper in CoChat — free account

Abstract

Although recent epidemiologic studies have established that patients with chronic medical illness and depressed mood are more disabled than euthymic patients, detailed data on the benefits and risks of antidepressant treatment in medically high-risk patients have been slow to accumulate. The authors have examined multiple outcome indicators in patients with disabling chronic obstructive pulmonary disease and comorbid depression. Thirty patients completed a 12-week, randomized controlled trial of nortriptyline. Nortriptyline was clearly superior to placebo for treatment of depression. Nortriptyline treatment was accompanied by marked improvements in anxiety, certain respiratory symptoms, overall physical comfort, and day-to-day function; placebo effects were negligible. Physiological measures reflecting pulmonary insufficiency were generally unaffected by treatment. These data provide impetus for renewed efforts to improve recognition and treatment of mood disorders in even severely disabled medical patients.

Integrity signals

Registry

Crossref · 10.1016/s0033-3182(92)71995-1

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Depression predicts fatigue, shortness of breath, and disability in patients with heart disease or COPD, even after adjusting for severity of illness.

    “Depression has been found to predict fatigue, shortness of breath, and disability in patients with heart disease or COPD, even after adjusting for severity of illness.52–56”

    From Anxiety and Depression in COPD (2008) · cites this paper as [53]

  • Evidence for antidepressant therapy in COPD is limited, with only one small randomized placebo-controlled trial of treatment in patients with major depression having been published.

    “Evidence for antidepressant therapy in COPD is limited, with only one small, randomized, placebo-controlled trial53 of treatment in patients with major depression having been published.”

    From Anxiety and Depression in COPD (2008) · cites this paper as [53]

  • A small randomized placebo-controlled trial found high efficacy for nortriptyline in improving short-term outcomes for depression, anxiety, panic attacks, cognitive function, and overall disability in patients with major depression and COPD.

    “This study found high efficacy for nortriptyline, a tricyclic antidepressant, in improving short-term outcomes for depression, anxiety, panic attacks, cognitive function, and overall disability.”

    From Anxiety and Depression in COPD (2008) · cites this paper as [53]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Borson, S., McDonald, G. J., Gayle, T., Deffebach, M., Lakshminarayan, S., & VanTuinen, C.
Affiliations
University of Washington (US)
Venue
Psychosomatics
Publisher
Elsevier BV
Published
1992-05
Volume
33
Issue
2
Pages
190-201
ISSN
0033-3182 (ISSN-L)
DOI
10.1016/s0033-3182(92)71995-1
OpenAlex
W2040089352
Cited by
277
References
47
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 13 · 2013: 9 · 2012: 11
FWCI
2.23
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
nortriptyline, depression, chronic obstructive pulmonary disease, antidepressant treatment, comorbid depression, mood improvement, somatic symptoms, functional capacity, anxiety, pulmonary insufficiency, placebo effect, severely disabled patients
MeSH terms
Activities of Daily Living, Affect, Attitude to Health, Chronic Disease, Depressive Disorder, Dyspnea, Female, Humans, Lung Diseases, Obstructive, Male, Middle Aged, Nortriptyline, Patient Compliance, Placebos, Prednisone, Psychiatric Status Rating Scales

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review